Alzheimerova choroba – všetky zdroje
1. Dmasio AR. Alzheimer’s disease and related dementias. In: Bennett CJ, Plum F, eds.
Cecil textbook of medicine. 20th edn. Philadelphia, PA: WB Saunders. 1996: p 1992–
1996
2. Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radical
Biol Med 1997; 23: 134–147
3. Shin RW. Interaction of aluminum with paired helical filament tau is involved in
neurofibrially pathology of Alzheimer’s disease. Gerontol 1997; 43(suppl 1): 16–23
4. Zapatero MD, Garcia de Jalon A, Pascual F et al. Serum aluminum levels in
Alzheimer’s disease and other senile dementias. Biol Trace Element Res 1995; 47:
235–240
5. Frolich L, Riederer, P. Free radical mechanisms in dementia of the Alzheimer’s type
and the potential for antioxidative treatment. Drug Res 1995; 45: 443–446
6. Walton J et al. Uptake of trace amounts of aluminum into the brain from drinking
water. Neurotoxicology 1995; 16: 187–190
7. Garcia CA, Reding MJ, Blass JP. Over diagnosis of dementia. J Am Ger Soc 1981;
29: 407–410
8. Smith JS, Kiloh LG. The investigation of dementia. Results in 200 consecutive
admissions. Lancet 1981; 1: 824–827
9. Weinreb HJ. Fingerprint patterns in Alzheimer’s disease. Arch Neurol 1985; 42: 50–
54
10. Kuller LH. Hormone replacement therapy and its potential relationship to dementia.
JAGS 1996; 44: 878–880
11. Paganini-Hill A. Oestrogen replacement therapy and Alzheimer’s disease. Br J Obstet
Gyn 1996; 103(suppl 13): 80–86
12. Honjo H, Tanaka K, Kashiwagi T et al. Senile dementia – Alzheimer’s type and
estrogen. Horm Metab Res 1995; 27: 204–207
13. Smalheiser NR, Swansom DR. lisking estrogen to Alzheimer’s disease. An
informatics approach. Neurology 1996; 47: 809–810
14. Matthews KA, Kuller LH, Wing RR et al. Prior to use of estrogen replacement
therapy, are uses healthier than nonusers? Am J Epidemiol 1996; 143: 971–978
15. Nolan CR, CeGoes JJ, Alfrey AC et al. Aluminum and lead absorption from dietary
sources in women ingesting calcium citrate. Southern Med J 1994; 87: 894–898
16. Glick JL. Dementias. The role of magnesium deficiency and hypothesis concerning
the pathogenesis of Alzheimer’s disease. Med Hypoth 1990; 31: 211–225
17. Tucker DM, Penland JG, Sandstead HH et al. Nutrition status and brain function in
aging. Am J Clin Nutr 1990; 52: 93–102
18. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative
diseases of aging. Proc Natl Acad Sci 1993; 90: 7915–7922
19. Smith MA, Perry G, Richey PL et al. Oxidative damage in Alzheimer’s disease.
Nature 1996; 382: 120–121
20. Jama JW, Launer LJ, Witteman JC et al. Dietary antioxidants and cognitive function
in a population-based sample of older persons. Am J Epidem 1996; 144: 275–280
21. Evans DA and Morris MC. Is a randomized trial of antioxidants in the primary
prevention of Alzheimer disease warranted. Alzheimer Dis Assoc Disorders 1996;
10(suppl 1): 45–49
22. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s
disease. Ann Neurol 1992; 32: S128–132
23. Spagnoli A et al. Long-term acetyl-L-carnitine treatment in Alzheimer’s disease.
Neurology 1991; 41: 1726–1732
24. Chen MF, Chen LT, Gold M et al. Plasma and erythrocyte thiamin concentration in
geriatric outpatients. J Am Coll Nutr 1996; 15: 231–236
25. Meador KJ, Nichols ME, Franke P et al. Evidence for a central cholinergic effect of
high dose thiamine. Ann Neurol 1993; 34: 724–726
26. Meador K. Preliminary findings of high-dose thiamine in dementia of Alzheimer’s
type. J Geriatr Psychiatry Neurol 1993; 6: 222–229
27. Benton D, Fordy J,and Haller J. The impact of long-term vitamin supplementation on
cognitive functioning. Psychopharmacol 1995; 117: 298–305
28. van Goor L, Woiski MD, Lagaay AM et al. Review: cobalamin deficiency and mental
impairment in elderly people. Age Ageing 1995; 24: 536–542
29. Shevell MI, Rosenblatt DS. The neurology of cobalamin. Can J Neurol Sci 1992; 19:
472–486
30. Yao Y, Lu-Yao G, Mesches DN et al. Decline of serum cobalamin levels with
increasing age among geriatric outpatients. Arch Fam Med 1994; 3: 918–922
31. Savage DG, Lindenbaum J, Stabler SP et al. Sensitivity of serum methylmalonic acid
and total homocysteine determinations for diagnosing cobalamin deficiency. Am J
Med 1994; 96: 239–246
32. Norman EJ, Morrison JA. Screening elderly populations for cobalamin (vitamin B 12
) deficiency using the urinary methylmalonic acid assay by gas chromatography mass
spectrophotometry. Am J
33. Nilsson K, Gustafson L, Faldt R et al. Plasma homocysteine in relationship to serum
cobalamin and blood folate in a psychogeriatric population. Eur J Clin Invest 1994;
24: 600–606
33. Healton EB, Savage DH, Brust JC et al. Neurologic aspects of cobalamin deficiency.
Medicine 1991; 70: 229–245
34. Martin DC, Francis J, Protetch J et al. Time dependency of cognitive recovery with
cobalamin replacement. A report of a pilot study. J Am Geriatric Soc 1992; 40: 168–
172
35. Levitt AJ, Karlinsky H. Folate, vitamin B 12 and cognitive impairment in patients
with Alzheimer’s disease. Acta Psychiatr Scand 1992; 86: 301–305
36. Kristensen MO, Gulmann MC, Christensen JE et al. Serum cobalamin and
methylmalonic acid in Alzheimer dementia. Acta Neurol Scand 1993; 87: 475–481
37. Constantinidis J. The hypothesis of zinc deficiency in the pathogenesis of
neurofibrillary tangles. Med Hypoth 1991; 35: 319–323
38. Burnet FM. A possible role of zinc in the pathology of dementia. Lancet 1981; 1:
186–188
39. Tully CL, Snowdon DA, Markesbery WR. Serum zinc, senile plaques, and
neurofibrillary tangles. Findings from the Nun Study. Neuroreport 1995; 6: 2105–
2108
40. Constantinidis J. Treatment of Alzheimer’s disease by zinc compounds. Drug
Develop Res 1992; 27: 1–14
41. Cuajungco MP, Lees GJ. Zinc and Alzheimer’s disease. Is there a direct link? Brain
Res Brain Res Rev 1997; 23: 219–236
42. Furuta A, Price DL, Pardo CA et al. Localization of superoxide dismutases in
Alzheimer’s disease and Down’s syndrome neocortex and hippocampus. Am J Pathol
1995; 146: 357–367
43. Rosenberg G, Davis KL. The use of cholinergic precursors in neuropsychiatric
diseases. Am J Clin Nutr 1982; 36: 709–720
44. Levy R, Little A, Chuaqui P, Reith M. Early results from double blind, placebo
controlled trial of high dose phosphatydylcholine in Alzheimer’s Disease. Lancet
1982; 1: 474–476
45. Sitaram N, Weingartner B, Gaine ED, a Cillin JC. Choline: selective enhancement of
serial learning and encoding of low imagery words in man. Life Sci 1978; 22: 1555–
1560
46. Cenacchi T, Bertoldin T, Farina C et al. Cognitive decline in the elderly. A doubleblind, placebo-controlled multicenter study on efficacy of phosphatidylserine
administration. Aging 1993; 5:
48. Engel RR, Satzger W, Gunther W et al. Double-blind cross-over study of
phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type.
Eur Neuropsychopharmacol 1992; 2:149–155
49. Crook T, Petri W, Wells C et al. Effects of phosphatidylserine in Alzheimer’s disease.
Psychopharmacol Bull 1992; 28: 61–66
50. Crook TH, Tinklenberg J, Yeseavage J et al. Effects of phosphatidylserine in ageassociated memory impairment. Neurology 1991; 41: 644–649
51. Funfgeld EW, Baggen M, Nedwidek P et al. Double-blind study with
phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s
type (SDAT). Prog Clin Biol Res 1989;
52. Amaducci L. Phosphatidylserine in the treatment of Alzheimer’s disease: results of a
multicenter study. Psychopharmacol Bull 1988; 24: 1030–1034
53. Nerozzi D, Aceti F, Melia E et al. Phosphatidylserine in age-related disturbance of
memory. Clin Terapeutica 1987; 120: 399–404
54. Palmieri G, Palmieri R, Inzoll MR et al. Double-blind controlled trial of
phosphatidylserine in patients with senile mental deterioration. Clin Trials J 1987; 24:
73–83
55. Villardita C, Grioli S, Slameri G et al. Multicentre clinical trial of brain
phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J
1987; 24: 84–93
56. Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A et al. Effect of phosphatidylserine
in demented patients. Acta Neurol Scand 1986; 73: 136–140
57. Bowman B. Acetyl-carnitine and Alzheimer’s disease. Nutr Rev 1992; 50: 142–144
58. Carta A et al. Acetyl-L-carnitine and Alzheimer’s disease. Pharmacological
considerations beyond the cholinergic sphere. Ann NY Acad Sci 1993; 695: 324–326
59. Calvani M et al. Action of acetyl-L-carnitine in neurodegneration and Alzheimer’s
disease. Ann NY Acad Sci 1993; 663: 483–486
60. Pettegrew JW et al. Clinical and neurochemical effects of acetyl-L-carnitine in
Alzheimer’s disease. Neurobiol Aging 1995; 16: 1–4
61. Sano M et al. Double-blind parallel design pilot study of acetyl levocarnitine in
patients with Alzheimer’s disease. Arch Neurol 1992; 49: 1137–1141
62. Vecchi GP et al. Acetyl-L-carnitine treatment of mental impairment in the elderly.
Evidence from a multicenter study. Arch Gerontol Geriatr 1991; 2: 159–168
63. Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs
Exp Clin Res 1994; 20: 169–176
64. Cipolli C, Chiari G. Effects of L-acetylcarnitine on mental deterioration in the aged.
Initial results. Clin Ter 1990; 132: 479–510
65. Kalimi M, Regelson W. The biological role of dehydroepiandrosterone. New York: de
Gruyter. 1990
66. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women.
Potential remedial effects. Ann N Y Acad Sci 1995; 774: 128–142
67. Morales AJ et al. Effects of replacement dose of dehydroepiandrosterone in men and
women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360–1367
68. DeFeudis FV, ed. Ginkgo biloba extract (EGb 761). Pharmacological activities and
clinical applications. Paris: Elsevier. 1991
69. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136–1139
70. Kanowski S et al. Proof of the efficacy of the Ginkgo biloba special extract Egb 761
in outpaitents suffering from mild to moderate primary degenerative dementia of the
Alzheimer type of multi-infarct dementia. Phytomedicine 1997; 4: 3–13
71. Le Bars PL et al. A placebo-controlled, double-blind, randomized trial of an extract of
Ginkgo biloba for dementia. JAMA 1997; 278: 1327–1332
72. Skolnick A. Old Chinese herbal medicine used for fever yields possible new
Alzheimer disease therapy. JAMA 1997; 277: 776
73. Xu SS, Gao ZX, Weng Z et al. Efficacy of tablet Hyperzine A on memory, cognition
and behavior in Alzheimer’s disease. Acta Pharmacologica Sinica 1995; 16: 391–395